Literature DB >> 21498473

Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study.

Chun-Ru Chien1, Shan-Yu Su, Lorenzo Cohen, Hsiang-Wen Lin, Richard Tsong Lee, Ya-Chen Tina Shih.   

Abstract

UNLABELLED: Hypotheses. The authors hypothesized that the use of alternative medicine, in the form of Chinese medicine (CM), among patients in the continuing care phase of nasopharyngeal carcinoma (NPC) in Taiwan is higher than the use in a matched control group of noncancer individuals. STUDY
DESIGN: This was a case-control study.
METHODS: Using a population-based claim database, the authors identified 181 long-term survivors of NPC and 905 matched controls. They obtained information on CM use and associated cost as outcome measures. Descriptive analysis and regression models were applied to examine the association between NPC and the outcome measures.
RESULTS: The unadjusted CM initiation (34% vs 32%; P = .54), intensity of use (2.15 vs 1.73 visits; P = .37), and cost (US$79 vs US$58; P = .16) were higher for patients in the NPC group than for those in the control group. Regression analyses suggested that the NPC group had significantly more CM visits (1.01; 95% confidence interval = 0.07-1.96), and more than 50% of these visits were related to cancer.
CONCLUSION: The authors confirmed their hypotheses that the use of CM in the continuing care phase by patients with NPC in Taiwan was higher than the use in their matched, noncancer counterparts. These findings suggest that current clinical surveillance strategies for NPC might not meet patients' physical and emotional needs.

Entities:  

Mesh:

Year:  2011        PMID: 21498473     DOI: 10.1177/1534735411403308

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  8 in total

1.  Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis.

Authors:  Te-Chun Hsia; Chih-Yen Tu; Hsin-Yuan Fang; Ji-An Liang; Chia-Chin Li; Chun-Ru Chien
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Optimal interval of surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: population level evidence in addition to controlled trial.

Authors:  William Tzu-Liang Chen; Tao-Wei Ke; Yu-Min Liao; Chia-Chin Li; Chun-Ru Chien
Journal:  J Gastrointest Oncol       Date:  2015-06

3.  Cost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysis.

Authors:  Hsin-Yuan Fang; Fei-Yuan Hsiao; Hsu-Chih Huang; Yu-Sen Lin; Chih-Yi Chen; Shwn-Huey Shieh; Pin-Ru Chen; Chein-Kuang Chen; Chun-Ru Chien
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

4.  Cost-effectiveness of chemotherapy combined with thoracic radiotherapy versus chemotherapy alone for limited stage small cell lung cancer: A population-based propensity-score matched analysis.

Authors:  Chun-Ru Chien; Te-Chun Hsia; Chih-Yi Chen
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

5.  A metabolic investigation of anticancer effect of G. glabra root extract on nasopharyngeal carcinoma cell line, C666-1.

Authors:  Chaopan Zheng; Ling Han; Shihai Wu
Journal:  Mol Biol Rep       Date:  2019-05-07       Impact factor: 2.316

6.  Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head & neck cancer and health-related quality of life: a retrospective study.

Authors:  Li Yanwei; He Feng; Wang Xudong; Pan Zhanyu
Journal:  BMC Complement Med Ther       Date:  2022-08-10

7.  Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies.

Authors:  Sheng-Miauh Huang; Li-Yin Chien; Cheng-Jeng Tai; Ling-Ming Tseng; Ping-Ho Chen; Chen-Jei Tai
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-21       Impact factor: 2.629

8.  Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells.

Authors:  Li Yanwei; Yang Yinli; Zhanyu Pan
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-13       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.